A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Trial Profile

A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs APX 001 (Primary)
  • Indications Aspergillosis; Candidiasis; Mycoses
  • Focus Adverse reactions; First in man
  • Sponsors Amplyx Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2017 Results from this and another phase I trial presented in an Amplyx Pharmaceuticals media release.
    • 09 Oct 2017 According to an Amplyx Pharmaceuticals media release, results from this trial have been presented at IDWeek 2017.
    • 08 Oct 2017 Results presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top